[Translation] A randomized, double-blind, controlled phase III bridging clinical study evaluating the efficacy of Uproleselan combined with chemotherapy versus chemotherapy alone in Chinese subjects with relapsed or refractory acute myeloid leukemia
本研究的主要目的是比较接受Uproleselan联合化疗与单纯化疗的受试者的总生存期(OS)。
[Translation] The primary objective of this study was to compare overall survival (OS) in subjects receiving Uproleselan in combination with chemotherapy versus chemotherapy alone.